EMERGENT BIOSOLUTIONS INC. Form 8-K (June 11, 2020)

Summary

A Form 8-K current report of Emergent BioSolutions Inc., dated June 11, 2020 and signed by Richard S. Lindahl, Executive Vice President, Chief Financial Officer and Treasurer. Under Item 7.01 the company issued a press release (Exhibit 99) announcing an agreement to support the manufacturing of AstraZeneca's COVID-19 vaccine candidate. Under Item 8.01 it reports that on June 10, 2020 Emergent Manufacturing Operations Baltimore, LLC entered into an agreement with AstraZeneca Pharmaceuticals LP to provide CDMO services, technology transfer, analytical testing and drug substance process and performance qualification, and to reserve large-scale manufacturing capacity through 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2020

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware | 001-33137 | 14-1902018
(State or other jurisdiction | (Commission File Number) | (IRS Employer
of incorporation) | Identification No.)

400 Professional Drive , Suite 400 ,

Gaithersburg , Maryland 20879

(Address of principal executive offices, including zip code)

( 240 ) 631-3200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, Par Value $0.001 per share | EBS | New York Stock Exchange

Item 7.01 Regulation FD Disclosure.

On June 11, 2020, Emergent BioSolutions Inc. (the “Company”) issued a press release announcing an agreement to support the manufacturing of AstraZeneca’s vaccine candidate for COVID-19. A copy of the press release related to such announcement is furnished as Exhibit 99 to this Current Report on Form 8-K.

Item 8.01 Other Events.

On June 10, 2020, Emergent Manufacturing Operations Baltimore, LLC entered into an agreement with AstraZeneca Pharmaceuticals LP to provide CDMO services, technology transfer, analytical testing, drug substance process and performance qualification and will reserve certain large-scale manufacturing capacity through 2020.

Item 9.01 Financial Statements and Exhibits .

(d) Exhibits.

Exhibit No. | Description
99 | Press release issued by the Company on June 11, 2020.
101 | Emergent BioSolutions Inc. Current Report on Form 8-K, dated June 11, 2020, formatted in XBRL (Extensible Business Reporting Language): Cover Page. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EMERGENT BIOSOLUTIONS INC.
Dated: June 11, 2020 | By: | /s/ RICHARD S. LINDAHL
Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer

File and source

File

SEC_EBS_8-K_filed2020-06-11_0001367644-20-000106.htm

Size

44,998 bytes

SHA-256

85571c73da8c66562259a5a531d8af850cb6b504d2b62c2b9e95e4909406319c

Our copy

SEC_EBS_8-K_filed2020-06-11_0001367644-20-000106.htm

Original

www.sec.gov